Gyre Therapeutics, Inc.
GYRE
$8.58
-$0.2269-2.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -6.78% | -8.49% | -0.29% | 8.89% | 7.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -6.78% | -8.49% | -0.29% | 8.89% | 7.09% |
| Cost of Revenue | -16.22% | -16.64% | -15.59% | -9.47% | -6.53% |
| Gross Profit | -6.38% | -8.14% | 0.42% | 9.79% | 7.75% |
| SG&A Expenses | -2.90% | 8.71% | -4.81% | 4.96% | 2.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.00% | 3.15% | -9.89% | -0.88% | -1.61% |
| Operating Income | -15.53% | -54.92% | 108.84% | 99.64% | 88.96% |
| Income Before Tax | 130.17% | -451.03% | -804.19% | -788.76% | -843.31% |
| Income Tax Expenses | -37.52% | -36.43% | 23.08% | 49.45% | 60.84% |
| Earnings from Continuing Operations | 120.94% | -742.29% | -2,583.23% | -1,978.52% | -1,789.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 22.00% | 38.62% | -18.20% | -97.82% | -270.43% |
| Net Income | 113.00% | -2,033.69% | -3,059.62% | -33,680.46% | -3,148.78% |
| EBIT | -15.53% | -54.92% | 108.84% | 99.64% | 88.96% |
| EBITDA | -12.35% | -50.94% | 98.22% | 91.27% | 79.09% |
| EPS Basic | 111.36% | -1,827.29% | -12,447.42% | -6,136.60% | -2,212.80% |
| Normalized Basic EPS | 783.44% | -130.89% | -7.55% | 2,222.22% | 52.06% |
| EPS Diluted | 108.21% | -2,950.00% | -24,812.00% | -4,826.00% | -2,249.09% |
| Normalized Diluted EPS | 353.03% | -153.55% | -54.25% | 132.35% | -20.32% |
| Average Basic Shares Outstanding | 29.26% | 28.55% | 59.84% | 122.53% | 314.11% |
| Average Diluted Shares Outstanding | 21.63% | 20.80% | 53.13% | 120.08% | 386.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |